Cue Biopharma (CUE) Capital Expenditures (2017 - 2025)

Cue Biopharma has disclosed Capital Expenditures across 8 years of filings, most recently posting $27000.0 for Q2 2025.

• Capital Expenditures for Q2 2025 came in at $27000.0, up 170.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $177000.0 (up 168.18% YoY), and the FY2025 annual result was $177000.0, up 168.18% from the prior year.
• Capital Expenditures came in at $27000.0 for Q2 2025 at Cue Biopharma, down from $150000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $648000.0 in Q1 2021 to a low of -$1000.0 in Q3 2024.
• The 4-year median for Capital Expenditures is $27000.0 (2022), against an average of $94788.5.
• Across the five-year window, Capital Expenditures plunged 99.96% in 2021 and jumped 2464.1% in 2022, its largest moves.
• Cue Biopharma's Capital Expenditures stood at $39.0 in 2021, then surged by 2464.1% to $1000.0 in 2022, then soared by 100.0% to $2000.0 in 2024, then surged by 1250.0% to $27000.0 in 2025.
• The last three Capital Expenditures figures came in at $27000.0 (Q2 2025), $150000.0 (Q1 2025), and $2000.0 (Q4 2024), per Business Quant data.